SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
program that leverages a proprietary shuttle technology to enhance brain delivery of therapeutic agents to treat Alzheimer's Disease SciNeuro and Novartis will collaborate during early development, with Novartis leading subsequent development and commercialization worldwide SciNeuro Pharmaceuticals today announced it has entered into a worldwide licensing and collaboration agreement with Novartis Pharma AG, to advance SciNeuro's novel amyloid beta targeted antibody program for the treatment of Alzheimer's Disease. The program has identified de novo antibody candidates that incorporate SciNeuro's proprietary blood brain barrier shuttle technology and offer potential differentiation from existing amyloid beta targeted agents. SciNeuro and Novartis will collaborate during early development. Novartis will lead all subsequent product development and commercialization on a worldwide basis. "The anti-amyloid program represents one of SciNeuro's key strategic R&D priorities to target
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs [Yahoo! Finance]Yahoo! Finance
- Gradalis Appoints Steven D. Weinstein as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment [Yahoo! Finance]Yahoo! Finance
- Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investmentGlobeNewswire
- New Investors: 3 Stocks to Build Your Portfolio Around in 2026 [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 11/25/25 - Form 6-K
- 11/20/25 - Form 6-K
- 11/5/25 - Form 6-K
- NVS's page on the SEC website